What is ALVO (ALVO) stock price today?

ALVO (ALVO) is currently trading at $5.24, up 0.96% today.

What is ALVO P/E ratio?

ALVO's P/E ratio is -8.40. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ALVO return on equity (ROE)?

ALVO's return on equity (ROE) is 76.83%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is ALVO's market cap?

ALVO has a market capitalization of $1.77B.

NASDAQ · Drug Manufacturers - Specialty & Generic

ALVO (ALVO) Stock

$5.24 +0.96% NASDAQ: ALVO Healthcare

Valuation

Metric	Value
Price	$5.24
Market Cap	$1.77B
P/E Ratio	-8.40
P/B Ratio	-9.15
P/S Ratio	3.38
EPS (TTM)	$0.10
52-Week High	$9.25
52-Week Low	$2.94
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	76.83%
ROA	-11.31%
ROCE	3.77%
Gross Margin	13.31%
Operating Margin	13.31%
Net Margin	-36.51%
Debt/Equity	-7.58
Current Ratio	1.89

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$37.0M	$83.0M	$91.0M	$490.0M	$586.0M
Operating Profit	$-235.0M	$-346.0M	$-355.0M	$70.0M	$78.0M
Net Profit	$-102.0M	$-514.0M	$-552.0M	$-232.0M	$28.0M
EPS	$-3.25	$-2.60	$-2.43	$-0.87	$0.10
Op Margin	-640.3%	-417.3%	-388.1%	14.2%	13.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$598.0M	$828.0M	$950.0M	$1.2B	$1.5B
Total Liabilities	$734.0M	$1.4B	$1.9B	$1.6B	$1.8B
Cash	$18.0M	$66.0M	$11.0M	$51.0M	$172.0M
Borrowings	$523.0M	$805.0M	$1.1B	$1.2B	$1.4B

Latest News

Alvotech Faces 'Soft' Q2 but Well Positioned to Benefit From Upcoming Biosimilar Opportunity, UBS Says MT Newswires · Jul 6, 2026 Transactions of Managers and Closely Associated Persons GlobeNewswire · Jul 3, 2026 Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering Simply Wall St. · Jul 2, 2026 Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO) Simply Wall St. · Jul 2, 2026 Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Fed Chair Warsh's International Debut MT Newswires · Jul 1, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-228.0M	$-312.0M	$-312.0M	$-237.0M	$-50.0M
Investing Cash Flow	$-81.0M	$-113.0M	$-93.0M	$-76.0M	$-169.0M
Financing Cash Flow	$0	$157.0M	$-7.0M	$-5.0M	$-10.0M
Net Cash Flow	$-14.0M	$49.0M	$-55.0M	$40.0M	$121.0M
Free Cash Flow	$-269.0M	$-361.0M	$-359.0M	$-294.0M	$-115.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.09
EV / EBITDA	-2084.00
FCF Yield	-18.08%
Quick Ratio	0.96
Interest Coverage	0.30
Return 1Y	-65.28%
Return 3Y	-68.42%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AMPH	$22.96	+1.91%	12.02	$1.01B	0.00%
BHVN	$15.74	+3.08%	-6.11	$2.37B	0.00%
COLL	$24.00	-2.48%	16.45	$778.41M	0.00%
EVOEvotec SE	$2.01	-6.07%	-3.26	$713.93M	0.00%
HROW	$36.97	+0.16%	14.50	$1.38B	0.00%

About ALVO

ALVO is led by CEO Lisa Graver, employs 1,012 people, headquartered in IS, publicly traded since 2022.

ALVO stock trades at $5.24 with a market capitalization of $1.77B. The stock is valued at a price-to-earnings (P/E) ratio of -8.40, price-to-book of -9.15, price-to-sales of 3.38. Over the past 52 weeks the stock has ranged between $2.94 and $9.25, and currently trades 43.4% below its 52-week high.

On profitability, ALVO generates a return on equity (ROE) of 76.83% — well above the market average, a sign of a high-quality business, return on capital employed of 3.77%, an operating margin of 13.31%, a net profit margin of -36.51%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides